Slow Capital Inc. Lowers Position in 10x Genomics, Inc. (NASDAQ:TXG)

Slow Capital Inc. decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 81.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,584 shares of the company's stock after selling 94,756 shares during the quarter. Slow Capital Inc.'s holdings in 10x Genomics were worth $310,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after purchasing an additional 1,265 shares during the period. Capital Performance Advisors LLP acquired a new stake in 10x Genomics during the 3rd quarter worth $35,000. Blue Trust Inc. boosted its stake in 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after purchasing an additional 1,025 shares during the period. Sound Income Strategies LLC acquired a new stake in 10x Genomics during the 3rd quarter worth $46,000. Finally, Venturi Wealth Management LLC boosted its stake in 10x Genomics by 1,108.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company's stock worth $55,000 after purchasing an additional 2,240 shares during the period. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Price Performance

TXG traded down $0.01 during midday trading on Tuesday, reaching $14.84. 1,778,793 shares of the company's stock were exchanged, compared to its average volume of 1,964,182. The stock has a market capitalization of $1.80 billion, a PE ratio of -9.70 and a beta of 1.83. The business's 50-day moving average price is $15.08 and its 200 day moving average price is $17.82. 10x Genomics, Inc. has a 1-year low of $12.95 and a 1-year high of $51.22.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04. The company had revenue of $151.65 million during the quarter, compared to analysts' expectations of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The firm's quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.51) earnings per share. As a group, analysts expect that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TXG. Canaccord Genuity Group decreased their price target on shares of 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, October 10th. Weiss Ratings restated a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, January 18th. UBS Group reduced their target price on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating for the company in a research note on Wednesday, October 30th. JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, October 30th. Finally, Stephens restated an "overweight" rating and issued a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $23.86.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.